Live Biotherapeutic Zowell Reprograms Microbiota–Lipid Crosstalk to Enhance Cisplatin Efficacy in Lung Cancer
Cancers · 30.07.2026 · 18 (15) · 2447
DOI: 10.3390/cancers18152447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 30.07.2026. Verfasst von Bobban Subhadra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biom Pharmaceutical Corporation, Sarasota, FL 34234, USA. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, United States Department of Veterans Affairs, USF–Moffitt Microbiome Joint Research.
Abstract (Originalsprache)
Background
Lung cancer (LC) remains a leading cause of cancer-related mortality, often compounded by suboptimal chemotherapy efficacy and systemic toxicity. Emerging evidence implicates the gut microbiota in modulating tumor progression, immune function, and treatment outcomes.
Methods
We evaluated Zowell, a novel live bacterial therapeutic (LBT) developed via LiveBiom® co-fermentation, as an adjunct to cisplatin in a murine LC model harboring humanized microbiota. Mice were assigned to treatment groups: Zowell alone, cisplatin alone, their combination, and fecal microbiota transplantation (FMT) as a benchmark.
Results
Zowell monotherapy significantly reduced tumor burden, and its combination with cisplatin produced synergistic anti-tumor effects. 16S rRNA sequencing revealed enrichment of beneficial taxa (Bifidobacterium, Lactobacillus, and Allobaculum) and suppression of contextual genera (Clostridium and Akkermansia). Treatment rebalanced gut ecology, evidenced by a lowered Firmicutes/Bacteroidetes ratio and increased alpha diversity. Zowell outperformed FMT in reducing tumor volume and inflammatory indices. Lipidomic profiling of tumor tissues identified elevated levels of immunomodulatory lipid mediators, including resolvins and prostanoids, suggesting remodeling of the tumor microenvironment toward inflammation resolution and immune activation.
Conclusions
These findings support Zowell as a precision microbiome therapeutic that potentiates chemotherapy through gut microbial reprogramming and tumor lipid signaling modulation, offering translational promise for enhancing immunotherapeutic response and mitigating chemotherapy-induced toxicity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biom Pharmaceutical Corporation, Sarasota, FL 34234, USA.
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
- Research Service, James A. Haley Veterans Hospital, Tampa, FL 33612, USA.
- Division of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
ORCID-Profile: Prakasha Kempaiah, Lary A Robinson, Subhra Mohapatra
Förderung
- BLRD VA
- United States Department of Veterans Affairs
- USF–Moffitt Microbiome Joint Research
- U.S. Department of Veterans Affairs Research Career Scientist
- Biom Pharmaceutical Corporation
Zitieren
APA
Subhadra, B., Green, R., Kempaiah, P., Bobban, N., Robinson, L. A., & Mohapatra, S. (2026). Live Biotherapeutic Zowell Reprograms Microbiota–Lipid Crosstalk to Enhance Cisplatin Efficacy in Lung Cancer. Cancers, 18(15), 2447. https://doi.org/10.3390/cancers18152447
Vancouver
Subhadra B, Green R, Kempaiah P, Bobban N, Robinson LA, Mohapatra S. Live Biotherapeutic Zowell Reprograms Microbiota–Lipid Crosstalk to Enhance Cisplatin Efficacy in Lung Cancer. Cancers. 2026;18(15):2447. doi:10.3390/cancers18152447
BibTeX
@article{Subhadra2026,
author = {Subhadra, Bobban and Green, Ryan and Kempaiah, Prakasha and Bobban, Niya and Robinson, Lary A and Mohapatra, Subhra},
title = {Live Biotherapeutic Zowell Reprograms Microbiota–Lipid Crosstalk to Enhance Cisplatin Efficacy in Lung Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2447},
doi = {10.3390/cancers18152447}
}
EUVIMED